Single DermaVir immunization

Dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals

Julianna Lisziewicz, Nyasha Bakare, Sandra A. Calarota, Dénes Bánhegyi, János Szlávik, Eszter Újhelyi, Eniko R. Toke, Levente Molnár, Zsolt Lisziewicz, Brigitte Autran, Franco Lori

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background: The GIHU004 study was designed to evaluate the safety and immunogenicity of three doses of DermaVir immunization in HIV-infected subjects on fully suppressive combination antiretroviral therapy (cART). Methodology/Principal Findings: This first-in-human dose escalation study was conducted with three topical DermaVir doses targeted to epidermal Langerhans cells to express fifteen HIV antigens in draining lymph nodes: 0.1 mg DNA targeted to two, 0.4 mg and 0.8 mg DNA targeted to four lymph nodes. Particularly, in the medium dose cohort 0.1 mg DNA was targeted per draining lymph node via ~8 million Langerhans cells located in 80 cm2 epidermis area. The 28-days study with 48-week safety follow-up evaluated HIV-specific T cell responses against Gag p17, Gag p24 and Gag p15, Tat and Rev antigens. DermaVir-associated side effects were mild, transient and not dose-dependent. Boosting of HIV-specific effector CD4+ and CD8+ T cells expressing IFN-gamma and IL-2 was detected against several antigens in every subject of the medium dose cohort. The striking result was the dose-dependent expansion of HIV-specific precursor/memory T cells with high proliferation capacity. In low, medium and high dose cohorts this HIV-specific T cell population increased by 325-, 136,202 and 50,759 counts after 4 weeks, and by 3,899, 9,878 and 18,382 counts after one year, respectively, compared to baseline. Conclusions/Significance: Single immunization with the DermaVir candidate therapeutic vaccine was safe and immunogenic in HIV-infected individuals. Based on the potent induction of Gag, Tat and Rev-specific memory T cells, especially in the medium dose cohort, we speculate that DermaVir boost T cell responses specific to all the 15 HIV antigens expressed from the single DNA. For durable immune reactivity repeated DermaVir immunization might be required since the frequency of DermaVir-boosted HIV-specific memory T cells decreased during the 48-week follow up. Trial Registration: ClinicalTrial.gov NCT00712530.

Original languageEnglish
Article numbere35416
JournalPLoS One
Volume7
Issue number5
DOIs
Publication statusPublished - May 9 2012

Fingerprint

HIV Antigens
T-Lymphoid Precursor Cells
Immunization
T-cells
Human immunodeficiency virus 1
HIV-1
immunization
T-lymphocytes
HIV
antigens
Data storage equipment
T-Lymphocytes
dosage
Langerhans Cells
Lymph Nodes
DNA
Langerhans cells
lymph nodes
Safety
Antigens

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Lisziewicz, J., Bakare, N., Calarota, S. A., Bánhegyi, D., Szlávik, J., Újhelyi, E., ... Lori, F. (2012). Single DermaVir immunization: Dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. PLoS One, 7(5), [e35416]. https://doi.org/10.1371/journal.pone.0035416

Single DermaVir immunization : Dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. / Lisziewicz, Julianna; Bakare, Nyasha; Calarota, Sandra A.; Bánhegyi, Dénes; Szlávik, János; Újhelyi, Eszter; Toke, Eniko R.; Molnár, Levente; Lisziewicz, Zsolt; Autran, Brigitte; Lori, Franco.

In: PLoS One, Vol. 7, No. 5, e35416, 09.05.2012.

Research output: Contribution to journalArticle

Lisziewicz, J, Bakare, N, Calarota, SA, Bánhegyi, D, Szlávik, J, Újhelyi, E, Toke, ER, Molnár, L, Lisziewicz, Z, Autran, B & Lori, F 2012, 'Single DermaVir immunization: Dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals', PLoS One, vol. 7, no. 5, e35416. https://doi.org/10.1371/journal.pone.0035416
Lisziewicz, Julianna ; Bakare, Nyasha ; Calarota, Sandra A. ; Bánhegyi, Dénes ; Szlávik, János ; Újhelyi, Eszter ; Toke, Eniko R. ; Molnár, Levente ; Lisziewicz, Zsolt ; Autran, Brigitte ; Lori, Franco. / Single DermaVir immunization : Dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. In: PLoS One. 2012 ; Vol. 7, No. 5.
@article{b379e84d47bc4ba983982efb0e3140ca,
title = "Single DermaVir immunization: Dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals",
abstract = "Background: The GIHU004 study was designed to evaluate the safety and immunogenicity of three doses of DermaVir immunization in HIV-infected subjects on fully suppressive combination antiretroviral therapy (cART). Methodology/Principal Findings: This first-in-human dose escalation study was conducted with three topical DermaVir doses targeted to epidermal Langerhans cells to express fifteen HIV antigens in draining lymph nodes: 0.1 mg DNA targeted to two, 0.4 mg and 0.8 mg DNA targeted to four lymph nodes. Particularly, in the medium dose cohort 0.1 mg DNA was targeted per draining lymph node via ~8 million Langerhans cells located in 80 cm2 epidermis area. The 28-days study with 48-week safety follow-up evaluated HIV-specific T cell responses against Gag p17, Gag p24 and Gag p15, Tat and Rev antigens. DermaVir-associated side effects were mild, transient and not dose-dependent. Boosting of HIV-specific effector CD4+ and CD8+ T cells expressing IFN-gamma and IL-2 was detected against several antigens in every subject of the medium dose cohort. The striking result was the dose-dependent expansion of HIV-specific precursor/memory T cells with high proliferation capacity. In low, medium and high dose cohorts this HIV-specific T cell population increased by 325-, 136,202 and 50,759 counts after 4 weeks, and by 3,899, 9,878 and 18,382 counts after one year, respectively, compared to baseline. Conclusions/Significance: Single immunization with the DermaVir candidate therapeutic vaccine was safe and immunogenic in HIV-infected individuals. Based on the potent induction of Gag, Tat and Rev-specific memory T cells, especially in the medium dose cohort, we speculate that DermaVir boost T cell responses specific to all the 15 HIV antigens expressed from the single DNA. For durable immune reactivity repeated DermaVir immunization might be required since the frequency of DermaVir-boosted HIV-specific memory T cells decreased during the 48-week follow up. Trial Registration: ClinicalTrial.gov NCT00712530.",
author = "Julianna Lisziewicz and Nyasha Bakare and Calarota, {Sandra A.} and D{\'e}nes B{\'a}nhegyi and J{\'a}nos Szl{\'a}vik and Eszter {\'U}jhelyi and Toke, {Eniko R.} and Levente Moln{\'a}r and Zsolt Lisziewicz and Brigitte Autran and Franco Lori",
year = "2012",
month = "5",
day = "9",
doi = "10.1371/journal.pone.0035416",
language = "English",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Single DermaVir immunization

T2 - Dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals

AU - Lisziewicz, Julianna

AU - Bakare, Nyasha

AU - Calarota, Sandra A.

AU - Bánhegyi, Dénes

AU - Szlávik, János

AU - Újhelyi, Eszter

AU - Toke, Eniko R.

AU - Molnár, Levente

AU - Lisziewicz, Zsolt

AU - Autran, Brigitte

AU - Lori, Franco

PY - 2012/5/9

Y1 - 2012/5/9

N2 - Background: The GIHU004 study was designed to evaluate the safety and immunogenicity of three doses of DermaVir immunization in HIV-infected subjects on fully suppressive combination antiretroviral therapy (cART). Methodology/Principal Findings: This first-in-human dose escalation study was conducted with three topical DermaVir doses targeted to epidermal Langerhans cells to express fifteen HIV antigens in draining lymph nodes: 0.1 mg DNA targeted to two, 0.4 mg and 0.8 mg DNA targeted to four lymph nodes. Particularly, in the medium dose cohort 0.1 mg DNA was targeted per draining lymph node via ~8 million Langerhans cells located in 80 cm2 epidermis area. The 28-days study with 48-week safety follow-up evaluated HIV-specific T cell responses against Gag p17, Gag p24 and Gag p15, Tat and Rev antigens. DermaVir-associated side effects were mild, transient and not dose-dependent. Boosting of HIV-specific effector CD4+ and CD8+ T cells expressing IFN-gamma and IL-2 was detected against several antigens in every subject of the medium dose cohort. The striking result was the dose-dependent expansion of HIV-specific precursor/memory T cells with high proliferation capacity. In low, medium and high dose cohorts this HIV-specific T cell population increased by 325-, 136,202 and 50,759 counts after 4 weeks, and by 3,899, 9,878 and 18,382 counts after one year, respectively, compared to baseline. Conclusions/Significance: Single immunization with the DermaVir candidate therapeutic vaccine was safe and immunogenic in HIV-infected individuals. Based on the potent induction of Gag, Tat and Rev-specific memory T cells, especially in the medium dose cohort, we speculate that DermaVir boost T cell responses specific to all the 15 HIV antigens expressed from the single DNA. For durable immune reactivity repeated DermaVir immunization might be required since the frequency of DermaVir-boosted HIV-specific memory T cells decreased during the 48-week follow up. Trial Registration: ClinicalTrial.gov NCT00712530.

AB - Background: The GIHU004 study was designed to evaluate the safety and immunogenicity of three doses of DermaVir immunization in HIV-infected subjects on fully suppressive combination antiretroviral therapy (cART). Methodology/Principal Findings: This first-in-human dose escalation study was conducted with three topical DermaVir doses targeted to epidermal Langerhans cells to express fifteen HIV antigens in draining lymph nodes: 0.1 mg DNA targeted to two, 0.4 mg and 0.8 mg DNA targeted to four lymph nodes. Particularly, in the medium dose cohort 0.1 mg DNA was targeted per draining lymph node via ~8 million Langerhans cells located in 80 cm2 epidermis area. The 28-days study with 48-week safety follow-up evaluated HIV-specific T cell responses against Gag p17, Gag p24 and Gag p15, Tat and Rev antigens. DermaVir-associated side effects were mild, transient and not dose-dependent. Boosting of HIV-specific effector CD4+ and CD8+ T cells expressing IFN-gamma and IL-2 was detected against several antigens in every subject of the medium dose cohort. The striking result was the dose-dependent expansion of HIV-specific precursor/memory T cells with high proliferation capacity. In low, medium and high dose cohorts this HIV-specific T cell population increased by 325-, 136,202 and 50,759 counts after 4 weeks, and by 3,899, 9,878 and 18,382 counts after one year, respectively, compared to baseline. Conclusions/Significance: Single immunization with the DermaVir candidate therapeutic vaccine was safe and immunogenic in HIV-infected individuals. Based on the potent induction of Gag, Tat and Rev-specific memory T cells, especially in the medium dose cohort, we speculate that DermaVir boost T cell responses specific to all the 15 HIV antigens expressed from the single DNA. For durable immune reactivity repeated DermaVir immunization might be required since the frequency of DermaVir-boosted HIV-specific memory T cells decreased during the 48-week follow up. Trial Registration: ClinicalTrial.gov NCT00712530.

UR - http://www.scopus.com/inward/record.url?scp=84860745751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860745751&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0035416

DO - 10.1371/journal.pone.0035416

M3 - Article

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e35416

ER -